NCT06599697View on ClinicalTrials.gov

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

June 30, 2027

Conditions
Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Interventions
BIOLOGICAL

Intravenously administered pooled human immunoglobulin (IVIG)

IVIG 2g/kg every 4 weeks for 12 weeks (3 doses)

Trial Locations (5)

15260

University of Pittsburgh, Pittsburgh

21218

Johns Hopkins University, Baltimore

35233

University of Alabama at Birmingham, Birmingham

77030

University of Texas Health Science Center at Houston, Houston

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

collaborator

Octapharma USA, Inc.

UNKNOWN

lead

University of Alabama at Birmingham

OTHER

NCT06599697 - The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy | Biotech Hunter | Biotech Hunter